CL2014000736A1 - Proteina de fusion que comprende una variante de fgf21 y una region fc. - Google Patents

Proteina de fusion que comprende una variante de fgf21 y una region fc.

Info

Publication number
CL2014000736A1
CL2014000736A1 CL2014000736A CL2014000736A CL2014000736A1 CL 2014000736 A1 CL2014000736 A1 CL 2014000736A1 CL 2014000736 A CL2014000736 A CL 2014000736A CL 2014000736 A CL2014000736 A CL 2014000736A CL 2014000736 A1 CL2014000736 A1 CL 2014000736A1
Authority
CL
Chile
Prior art keywords
fgf21
variant
region
fusion protein
fusion
Prior art date
Application number
CL2014000736A
Other languages
English (en)
Inventor
R Boettcher Brian
S Daniels Douglas
Hamamatsu Norio
Licht Stuart
Craig Weldon Stephen
L Caplan Shari
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2014000736A1 publication Critical patent/CL2014000736A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CL2014000736A 2011-09-26 2014-03-25 Proteina de fusion que comprende una variante de fgf21 y una region fc. CL2014000736A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161539280P 2011-09-26 2011-09-26

Publications (1)

Publication Number Publication Date
CL2014000736A1 true CL2014000736A1 (es) 2014-10-03

Family

ID=46970456

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2014000736A CL2014000736A1 (es) 2011-09-26 2014-03-25 Proteina de fusion que comprende una variante de fgf21 y una region fc.
CL2016002215A CL2016002215A1 (es) 2011-09-26 2016-09-02 Proteina de fusion que comprende una variante del factor de crecimiento de fibroblastos 21 (fgf21) y una region fc, polinucleotido, vector, celula huesped; metodo para producir la proteina de fusion y composicion farmaceutica (divisional de sol. n° 736-14).

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2016002215A CL2016002215A1 (es) 2011-09-26 2016-09-02 Proteina de fusion que comprende una variante del factor de crecimiento de fibroblastos 21 (fgf21) y una region fc, polinucleotido, vector, celula huesped; metodo para producir la proteina de fusion y composicion farmaceutica (divisional de sol. n° 736-14).

Country Status (41)

Country Link
US (6) US9006400B2 (es)
EP (2) EP3321276B1 (es)
JP (4) JP6186361B2 (es)
KR (1) KR102085605B1 (es)
CN (2) CN103945871B (es)
AP (1) AP2014007543A0 (es)
AR (2) AR088044A1 (es)
AU (1) AU2012316052A1 (es)
BR (1) BR112014007069B1 (es)
CA (1) CA2849464C (es)
CL (2) CL2014000736A1 (es)
CO (1) CO6920257A2 (es)
CR (1) CR20140140A (es)
CU (2) CU24314B1 (es)
CY (2) CY1120928T1 (es)
DK (2) DK3321276T3 (es)
EA (1) EA039633B1 (es)
ES (2) ES2689762T3 (es)
GT (1) GT201400055A (es)
HR (2) HRP20181558T1 (es)
HU (2) HUE055584T2 (es)
IL (1) IL231533B (es)
IN (1) IN2014DN02043A (es)
JO (1) JO3476B1 (es)
LT (2) LT3321276T (es)
MA (1) MA35437B1 (es)
MX (1) MX350273B (es)
MY (1) MY166059A (es)
PE (2) PE20141551A1 (es)
PL (2) PL2760475T3 (es)
PT (2) PT3321276T (es)
RS (2) RS62341B1 (es)
SG (2) SG11201400538QA (es)
SI (2) SI2760475T1 (es)
SM (1) SMT202100595T1 (es)
TN (1) TN2014000109A1 (es)
TW (1) TWI593708B (es)
UA (1) UA113856C2 (es)
UY (2) UY34346A (es)
WO (1) WO2013049247A1 (es)
ZA (1) ZA201401700B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2344670T3 (es) 2006-07-25 2010-09-02 Lipoxen Technologies Limited Derivatizacion del factor estimulante de colonias granulociticas (gcsf).
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
FI4108671T3 (fi) 2010-10-01 2024-12-27 Modernatx Inc Muokattuja nukleosideja, nukleotideja ja nukleiinihappoja sekä niiden käyttötapoja
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
BR112013033175B1 (pt) 2011-07-01 2023-04-25 NGM Biopharmaceuticals, Inc Peptídeo quimérico, composição farmacêutica, célula transformada e uso do peptídeo quimérico
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JO3476B1 (ar) * 2011-09-26 2020-07-05 Novartis Ag بروتينات مندمجة لعلاج الاضطرابات الايضية
US9458214B2 (en) 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
AU2012318752B2 (en) 2011-10-03 2017-08-31 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
MX2014007233A (es) 2011-12-16 2015-02-04 Moderna Therapeutics Inc Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
EP3520821A1 (en) 2012-04-02 2019-08-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
CA2892152A1 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
AU2013370404B2 (en) 2012-12-27 2017-11-02 Ngm Biopharmaceuticals, Inc. Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015057908A1 (en) 2013-10-18 2015-04-23 Novartis Ag Methods of treating diabetes and related disorders
AU2014342630B2 (en) 2013-10-28 2020-11-05 Ngm Biopharmaceuticals, Inc. Cancer models and associated methods
HRP20200881T1 (hr) 2014-01-24 2020-09-04 Ngm Biopharmaceuticals, Inc. Antitijela koja vežu beta-klotho domenu 2 i postupci njihove uporabe
US20170065678A1 (en) * 2014-03-11 2017-03-09 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
DK3209681T3 (da) * 2014-10-23 2025-05-05 Ngm Biopharmaceuticals Inc Farmaceutiske sammensætninger omfattende peptidvarianter og fremgangsmåder til anvendelse deraf
TWI705071B (zh) 2014-10-24 2020-09-21 美商必治妥美雅史谷比公司 經修飾之fgf-21多肽及其用途
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
KR20160088656A (ko) 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
CA3185706A1 (en) 2015-08-03 2017-02-09 Novartis Ag Methods of treating fgf21-associated disorders
CA3003616C (en) 2015-11-09 2020-07-28 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
TW201731867A (zh) 2015-12-02 2017-09-16 賽諾菲公司 Fgf21變異體
WO2017201527A2 (en) * 2016-05-20 2017-11-23 President And Fellows Of Harvard College Gene therapy methods for age-related diseases and conditions
US11318186B2 (en) 2016-05-25 2022-05-03 Board Of Regents, The University Of Texas System Use of FGF21 in methods of increasing exocrine pancreatic secretion
EP3502143A4 (en) 2016-08-19 2020-07-15 Ampsource Biopharma Shanghai Inc. BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技(上海)有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759694B (zh) * 2016-08-19 2023-01-13 安源医药科技(上海)有限公司 双特异性抗体及其制备方法与用途
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
US10583174B2 (en) 2016-12-22 2020-03-10 Sanofi FGF21 compound / GLP-1R agonist combinations with optimized activity ratio
JP7181886B2 (ja) * 2017-03-14 2022-12-01 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 免疫グロブリンのFc部分を含む二重標的融合タンパク質
CN107050429B (zh) * 2017-04-01 2020-12-15 杭州生物医药创新研究中心 人成纤维生长因子21在制备用于治疗脑卒中药物中的应用
US11479591B2 (en) * 2017-05-05 2022-10-25 Trefoil Therapeutics, Inc. Recombinant modified fibroblast growth factors and therapeutic uses thereof
CN115109166B (zh) * 2017-11-24 2025-07-18 浙江道尔生物科技有限公司 一种治疗代谢疾病的多结构域活性蛋白
CN109929806B (zh) 2017-12-19 2020-05-08 北京吉源生物科技有限公司 一种表达glp1和fgf21的干细胞及其用途
CN119386162A (zh) * 2017-12-22 2025-02-07 诺华股份有限公司 用fgf21变体治疗代谢障碍的方法
US11679143B2 (en) 2018-02-08 2023-06-20 Sunshine Lake Pharma Co., Ltd. FGF21 variant, fusion protein and application thereof
WO2019243557A1 (en) * 2018-06-21 2019-12-26 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
JP7492463B2 (ja) 2018-07-03 2024-05-29 ブリストル-マイヤーズ スクイブ カンパニー Fgf-21製剤
CN111195234B (zh) * 2018-11-16 2022-08-26 鲁南制药集团股份有限公司 一种重组FGF21-Fc融合蛋白冻干粉制剂
EP3736574A1 (en) * 2019-05-07 2020-11-11 Atlas Antibodies AB A formulation comprising an isotope labeled fusion polypeptide
CN111944055B (zh) 2019-05-16 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
CN112386575B (zh) * 2019-08-19 2023-03-21 鲁南制药集团股份有限公司 一种代谢调节融合蛋白的冻干制剂
MX2022002747A (es) 2019-09-10 2022-04-06 Obsidian Therapeutics Inc Proteinas de fusion de ca2-il15 para regulacion ajustable.
AU2020408067B2 (en) 2019-12-20 2024-03-28 Novartis Ag Combination treatment of liver diseases using integrin inhibitors
JP6924291B2 (ja) 2020-01-21 2021-08-25 シャープ株式会社 端末装置、方法、および、集積回路
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
CN116322739A (zh) * 2020-07-02 2023-06-23 赛诺菲 Glp-1r激动剂/fgf21融合蛋白
WO2022101853A1 (en) 2020-11-16 2022-05-19 Novartis Ag Method of determining liver fibrosis
CN113265007B (zh) * 2021-06-10 2022-02-15 江南大学 一种治疗代谢疾病的融合蛋白及其制备方法和应用
CN115286705B (zh) * 2021-12-30 2024-05-10 长江大学 一种黄鳝成纤维细胞因子21重组蛋白及其制备方法和应用
WO2023245543A1 (en) * 2022-06-23 2023-12-28 Ampsource Biopharma Shanghai Inc. Uses of fgf21 fusion proteins
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2025108432A1 (en) * 2023-11-23 2025-05-30 Therorna Shanghai Co., Ltd. Circular rna encoding fgf21 and the use thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
DE3889853D1 (de) 1987-11-05 1994-07-07 Hybritech Inc Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7459540B1 (en) * 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
PT1232264E (pt) 1999-11-18 2009-11-26 Novartis Vaccines & Diagnostic Gene fgf-21 humano e produtos da expressão do gene
DE60030769T2 (de) 1999-12-23 2007-10-25 Zymogenetics, Inc., Seattle Verfahren zur behandlung von entzündungen
AU2002322394A1 (en) 2001-07-30 2003-02-17 Eli Lilly And Company Method for treating diabetes and obesity
CA2545539A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
EA200601121A1 (ru) * 2003-12-10 2006-10-27 Эли Лилли Энд Компани Мутеины фактора роста фибробластов 21
EP1751184B1 (en) * 2004-05-13 2009-09-30 Eli Lilly And Company Fgf-21 fusion proteins
EP2161281A1 (en) * 2004-09-02 2010-03-10 Eli Lilly & Company Muteins of fibroblast growth factor 21
JP2008528487A (ja) 2005-01-21 2008-07-31 イーライ リリー アンド カンパニー 心臓血管疾患を治療する方法
JOP20190083A1 (ar) * 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
KR20130086386A (ko) 2008-10-24 2013-08-01 아이알엠 엘엘씨 생합성적으로 생성된 피롤린-카르복시-리신, 및 피롤린-카르복시-리신 및 피롤리신 잔기의 화학적 유도체화를 통한 부위 특이적 단백질 변형
BRPI1011404B1 (pt) * 2009-05-05 2022-05-03 Amgen Inc Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira
US20120052069A1 (en) * 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
CA2764835A1 (en) * 2009-06-17 2010-12-23 Amgen Inc. Chimeric fgf19 polypeptides and uses thereof
US20130011401A1 (en) 2009-12-22 2013-01-10 Novartis Ag Soluble proteins for use as therapeutics
DE102010038140B4 (de) * 2010-10-13 2020-06-18 Hettich-Heinze Gmbh & Co. Kg Beschlag für eine Schiebetür
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
US9458214B2 (en) * 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
JO3476B1 (ar) * 2011-09-26 2020-07-05 Novartis Ag بروتينات مندمجة لعلاج الاضطرابات الايضية
US20170065678A1 (en) 2014-03-11 2017-03-09 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling

Also Published As

Publication number Publication date
MX350273B (es) 2017-08-31
JP2022058546A (ja) 2022-04-12
EP3321276A3 (en) 2018-06-20
US9006400B2 (en) 2015-04-14
SG10201602339XA (en) 2016-05-30
US20210386824A1 (en) 2021-12-16
JO3476B1 (ar) 2020-07-05
HRP20181558T1 (hr) 2018-11-30
EP3321276B1 (en) 2021-07-28
JP6567613B2 (ja) 2019-08-28
UY39119A (es) 2021-04-30
CY1124697T1 (el) 2022-07-22
PE20181159A1 (es) 2018-07-19
SG11201400538QA (en) 2014-06-27
CN107266579A (zh) 2017-10-20
IL231533B (en) 2018-06-28
PE20141551A1 (es) 2014-10-26
US11129874B2 (en) 2021-09-28
MA35437B1 (fr) 2014-09-01
HRP20211575T1 (hr) 2022-02-04
MX2014003677A (es) 2014-04-30
HK1251238A1 (en) 2019-01-25
US11944664B2 (en) 2024-04-02
UA113856C2 (xx) 2017-03-27
CA2849464A1 (en) 2013-04-04
EP2760475B1 (en) 2018-07-04
CR20140140A (es) 2014-07-15
RS57868B1 (sr) 2018-12-31
ES2689762T3 (es) 2018-11-15
CU20140034A7 (es) 2014-08-28
SMT202100595T1 (it) 2022-01-10
HUE055584T2 (hu) 2021-12-28
LT3321276T (lt) 2021-11-10
CY1120928T1 (el) 2019-12-11
NZ622998A (en) 2016-07-29
AR123908A2 (es) 2023-01-25
AR088044A1 (es) 2014-05-07
CN103945871A (zh) 2014-07-23
US10076554B2 (en) 2018-09-18
CN107266579B (zh) 2022-07-12
PL3321276T3 (pl) 2022-01-17
LT2760475T (lt) 2018-10-25
BR112014007069B1 (pt) 2020-12-15
CN103945871B (zh) 2017-04-26
HUE039857T2 (hu) 2019-02-28
CA2849464C (en) 2024-01-30
PT3321276T (pt) 2021-10-27
CL2016002215A1 (es) 2016-10-28
TN2014000109A1 (en) 2015-07-01
TW201326213A (zh) 2013-07-01
JP7339372B2 (ja) 2023-09-05
US20130079500A1 (en) 2013-03-28
SI2760475T1 (sl) 2018-10-30
JP2020007314A (ja) 2020-01-16
JP2014534172A (ja) 2014-12-18
KR102085605B1 (ko) 2020-03-06
WO2013049247A1 (en) 2013-04-04
AP2014007543A0 (en) 2014-03-31
CU24314B1 (es) 2018-02-08
MY166059A (en) 2018-05-22
US20160193297A1 (en) 2016-07-07
US9266935B2 (en) 2016-02-23
GT201400055A (es) 2017-09-28
DK2760475T3 (en) 2018-10-15
JP6186361B2 (ja) 2017-08-23
PL2760475T3 (pl) 2018-11-30
RS62341B1 (sr) 2021-10-29
US20150166622A1 (en) 2015-06-18
PT2760475T (pt) 2018-10-25
CU20150171A7 (es) 2016-07-29
ZA201401700B (en) 2015-01-28
AU2012316052A1 (en) 2014-04-17
KR20140069250A (ko) 2014-06-09
UY34346A (es) 2013-04-30
EP2760475A1 (en) 2014-08-06
EP3321276A2 (en) 2018-05-16
US20180369332A1 (en) 2018-12-27
TWI593708B (zh) 2017-08-01
CO6920257A2 (es) 2014-04-10
ES2895080T3 (es) 2022-02-17
DK3321276T3 (da) 2021-10-25
BR112014007069A2 (pt) 2017-03-28
EA201490695A1 (ru) 2015-10-30
JP2018023370A (ja) 2018-02-15
EA039633B1 (ru) 2022-02-18
CU24206B1 (es) 2016-10-28
US20240261372A1 (en) 2024-08-08
IL231533A0 (en) 2014-04-30
IN2014DN02043A (es) 2015-05-15
SI3321276T1 (sl) 2021-11-30

Similar Documents

Publication Publication Date Title
CL2014000736A1 (es) Proteina de fusion que comprende una variante de fgf21 y una region fc.
CL2014000195A1 (es) Proteina de fusion que comprende un primer y segundo dominio asociados a una señal positiva y a una señal negativa respectivamente; metodo para tratar paciente con cancer que comprende tratar con dicha proteina.
HRP20150241T1 (xx) Antikancerogeni fuzijski protein
CL2014001193A1 (es) Proteina de fusion que es un anticuerpo bi-específico con especifidad por ox40 humano y a albúmina de suero humano.
EP2728002A4 (en) HETERODIMIZED POLYPEPTIDE
CL2016000219A1 (es) Proteinas de fusión terapéutica.
BR112013018317A2 (pt) mutantes de fc do anticorpo resistentes a protease ativa
EP2403941A4 (en) REVERSE TRANSCRIPTASE FUSION PROTEINS STABILIZED
CO7020851A2 (es) Proteínas y péptidos modificados
EP2943512A4 (en) BOVINE FUSION ANTIBODY
SMT201500203B (it) Proteina di fusione anticancro
UY34017A (es) Proteínas de fusión y vacunas de combinación
HRP20170138T1 (hr) Ponovno dobivanje proteina
BR112013028892A2 (pt) proteína de ligação à biotina modificada, proteínas de fusão da mesma e aplicações
SI2697257T1 (sl) FC fuzijski proteini, ki vsebujejo nove linkerje ali razmestitve
EP2906602A4 (en) LYSINE-SPECIFIC LYSINE-SPECIFIC TRANSCRIPTIONING ACTIVATOR (TALE) - DEMETHYLASE-1 FUSION PROTEINS (LSD1)
BRPI0919346A2 (pt) lente oftálmica energizada.
EP2753635A4 (en) P53-ACTIVATING PEPTIDES
BR112013022279A2 (pt) proteína de fusão induzível anti-angiogênico e o seu uso
HRP20181690T1 (hr) Varijante protutijela fc
EP2697369A4 (en) NOVEL METHODS FOR PURIFYING PROTEINS
EP2545080A4 (en) NPP1 FUSION PROTEINS
HRP20190434T1 (hr) Fuzijski protein
CL2015003496A1 (es) Anticuerpos teicoicos anti-pared y conjugados.
DK3173102T3 (da) FGFR-FC-fusionsprotein og anvendelse deraf